Forms of antipsychotic therapy: Improved individual outcomes under personalised treatment of schizophrenia focused on depression

EPMA Journal

Volumn 2, Issue 4, 2011, Pages 391-402

  Babinkostova, Zoja ^a   Stefanovski, Branislav ^a  

^a University Clinic of Psychiatry   (Macedonia)

Author keywords

Antidepressant augmentation; Atypical antipsychotics; Calgary Depression Scale for Schizophrenia; Depressive symptoms; Hamilton Depression Rating Scale; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTRALINE; SULPIRIDE; VENLAFAXINE; ZIPRASIDONE;

AKINESIA; BECK DEPRESSION INVENTORY; CALGARY DEPRESSION SCALE FOR SCHIZOPHRENIA; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; EARLY DIAGNOSIS; HAMILTON SCALE; HUMAN; NONHUMAN; PATIENT ASSESSMENT; PERSONALIZED MEDICINE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; PSYCHOTIC DEPRESSION SCALE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; STRUCTURED INTERVIEW; TREATMENT OUTCOME;

EID: 84855255818     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1007/s13167-011-0103-0     Document Type: Review

References (84)

1. Heald A, Soni JM. Characterisation of depression in patients with schizophrenia. Indian J Med Res. 2008; 127: 544-50.
2. Moller HJ. Occurence and treatment of depressive comorbidity/cosyndromality in schizophrenic psychoses: conceptual and treatment issues. World J Biol Psychiatr. 2005; 6(4): 247-63.
3. Jeczmien P, Levkovitz Y, Weizman A, Carmel Z. Post-Psychotic Depression in Schizophrenia. Isr Med Assoc J. 2001; 3: 589-92.
4. Hafner H, Loffler W, Maurer K, Hambrecht M, Heiden W. Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatr Scand. 1999; 100(2): 105-18.
5. Knights A, Hirsch SR. Revealed depression and drug treatment for schizophrenia. Arch Gen Psychiatry. 1981; 38: 806-11.
6. Wassink TH, Flaum M, Nopoulos P, Andreasen NC. Prevalence of depressive symptoms early in the course of schizophrenia. Am J Psychiatry. 1999; 156: 315-6.
7. Mulholland C, Cooper S. The simptom of depression in schizophrenia and its managment. Adv Psychiatr Treat. 2000; 6: 169-77.
8. Johnson DAW. Studies of depressive symptoms in schizophrenia. Br J Psychiatr. 1981; 139: 89-101.
9. Muller M, Muller K, Fellgiebel A. Detection of depression in acute schizophrenia: Sensitivity and specificity of 2 standard observer rating scales. Can J Psychiatr. 2006; 51: 387-92.
10. Hafner H. Schizophrenia and depression: Chalenging the paradigm of two separate disease-A controled study of schizophrenia, depression and healthy controls. Schizophr Res. 2005; 77(1): 11-24.
11. Heiden W, Könnecke R, Maurer K, Ropeter D, Häfner H. Depression in the long term course of schizophrenia. Eur Arch Psychiatr Clin Neurosci. 2005; 255: 174-84.
12. Baynes D, Mulholland C, Cooper SJ, Montgomery RC, MacFlynn G, Lynch G, et al. Depressive symptoms in stable chronic schizophrenia: prevalence and relationship to psychopathology and treatment. Schizophr Res. 2000; 45(1): 47-56.
13. Sands JR, Harrow M. Depression during the longitudinal course of schizophrenia. Schizophr Bull. 1999; 25: 157-71.
14. Barnes TRE, Curson DA, Liddle PF, Patel M. The nature and prevalence of depression in chronic schizophrenic inpatients. Br J Psychiatr. 1989; 154: 486-91.
15. Glazer W. Depression and social adjustment among chronic schizophrenic outpatients. J Nerv Ment Dis. 1981; 169: 712-7.
16. Siris SG. Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents. Am J Psychiatr. 2000; 157(9): 1379-89.
17. Babinkostova Z, Stefanovski B. Depressive symptoms in schizophrenic patients. Medicus. 2010; 13(1): 126-31.
18. Murali T, Kumar S. Symptoms of depression in schizophrenia. Indian J Med Res. 2008; 127: 516-8.
19. Araujo F, Petribu K, Bastos O. Characterization of depressive syndrome in shizophrenic outpatients. Rev Bras Psiquiatr. 2002; 24(1): 18-25.
20. Chemerinski E, Bowie C, Anderson H, Harey P. Depression in schizophrenia: Methodological artifact or distinct feature of the illness? J Neuropsychiatry Clin Neurosci. 2008; 20(4): 431-40.
21. Conley R. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res. 2007; 90(1-3): 186-97.
22. Szafranski T. Comparision of depressive symptoms in schizophrenic patients and patients with major depressive disorder. Schizophr Res. 2003; 60(1): 27.
23. Freudenreich O, Tranulis C, Cather C, Henderson D, Evins E, Goff DC. Depressive symptoms in schizophrenia outpatients-prevalence and clinical correlates. Clin Schizophr Relat Psychoses. 2008; 2(2): 127-35.
24. Zisook S, McAdams LA, Kuck J, Harris MJ, Bailey A, Patterson TL, et al. Depressive symptoms in schizophrenia. Am J Psychiatr. 1999; 156: 1736-43.
25. Addington D, Addington J, Patten S, Remington G, Moamai J, Labelle A, et al. Double-blind, placebo-controlled comparision of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia. J Clin Psychopharmacol. 2002; 22(1): 20-5.
26. Birchwood MJ, Mason R, MacMillan F, Healy J. Depression, demoralisation and control over psychotic illness: a comparison of depressed and non-depressed patients with a chronic psychosis. Psychol Med. 1993; 23: 387-95.
27. Massimo M, Moliterno D, Rossattini M, Colasanti A. Depression in schizophrenia: Comparision of first and second-generation antipsychotic drugs. Schizophr Res. 2008; 99: 7-12.
28. Koreen AR, Siris SG, Chakos M, Alvir J, Mayerhoff D, Lieberman J. Depression in first-episode schizophrenia. Am J Psychiatr. 1993; 150(11): 1643-8.
29. Kirkpatrick B, Fischer B. Subdomains within the negative symptoms of schizophrenia. Schizophr Bull. 2006; 32: 246-9.
30. Gorna K, Jaracz K, Wrysczynska L, Rybakowski F. Quality of life and depression in schizophrenia. Adv Med Sci. 2007; 52(1): 108-11.
31. Subotnik KL, Nuechterlein KH, Asarnow RF. Depressive symptoms in the early course of schizophrenia: relationship to familial psychiatric illness. Am J Psychiatr. 1997; 154: 1551-6.
32. Hausmann A, Fleischhacker WW. Differential diagnosis of depressed mood in patients with schizophrenia: a diagnostic algorithm based on a review. Acta Psychiatr Scand. 2002; 106: 83-96.
33. Bottlender R, Strau A. Prevalence and background factors of depression in first admitted schizophrenic patients. Acta Psychiatr Scand. 2000; 101(2): 153-60.
34. Kholer C, Gur RC, Swanson CL, Petty R, Gur RE. Depression in schizophrenia: Association with neuropsychological defecits. Biol Psychiatr. 1988; 43: 165-72.
35. Kasckow JW, Zisook S. Co-occuring depressive symptoms in the older patient with schizophrenia. Drugs Aging. 2008; 25(8): 631-47.
36. Roy A, Thompson R, Kennedy S. Depression in chronic schizophrenia. Br J Psychiatr. 1983; 142: 465-70.
37. Addington D, Addington J, Maticka-Tyndale E. Specificity of the Calgary Depression Scale for schizophrenics. Schizophr Res. 1994; 11(3): 239-44.
38. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990; 3: 247-51.
39. Ramirez N, Sarro S, Arranz B, Sanchez J, Gonzalez J, San L. Instruments of depression assessment in schizophrenia. Actas Esp Psiquiatr. 2001; 29(4): 259-68.
40. Collins A, Remington G, Coulter K, Birkett K. Depression in schizophrenia: a comparison of three measures. Schizophr Res. 1996; 20: 205-9.
41. Felmet K, Zisook S, Kasckow J. Elderly patients with schizophrenia and depression: diagnosis and treatment. Clin Schizophr Relat Psychoses. 2011; 4(4): 239-50.
42. Tollefson GD, Sanger TM, Lu Y, Thieme ME. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatr. 1998; 55(3): 250-8.
43. Kinon BJ, Lipkovich I, Edwards SB, Adams DH, Ascher-Svanum H, Siris S. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol. 2006; 26(2): 157-62.
44. Ceskova E, Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry. 1993; 26: 121-4.
45. Kim SW, Kim SJ, Yoon BH, Kim JM, Shin IS, Hwang MY, et al. Diagnostic validity of assessment scales for depression in patients with schizophrenia. Psychiatr Res. 2006; 144(1): 57-63.
46. Hausmann A, Fleischhacer WW. Depression in patients with schizophrenia. CNS Drugs. 2000; 14(4): 289-99.
47. Mergui J, Jaworowski S, Lerner V. Quetiapine-associated depression in a patient with schizophrenia. Clin Neuropharmacol. 2005; 28(3): 133-5.
48. Quintin P, Thomas P. Efficacy of atypical antipsychotics in depressive syndromes. Encephale. 2004; 30(6): 583-9.
49. Siris S. Assessment and treatment of depression in schizophrenia. Psychiatr Ann. 1994; 24: 463-7.
50. Moller HJ. Drug treatment of depressive symptoms in schizophrenia. Clin Schizophr Relat Psychoses. 2008; 1(4): 328-40.
51. Correll CU, Leucht S, Kane JM. Lower risk of tardive dyskinesia associated with second generation antipsychotics: a systematic review of 1 year studies. Am J Psychiatr. 2004; 161(3): 414-25.
52. Tollefson GD, Sangera TM, Beasleya CM, Tran PV. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatr. 1998; 43(11): 803-10.
53. Tollefson GD, Andersena SW, Trana PV. The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. Biol Psychiatr. 1999; 46(3): 365-73.
54. Aguilar E, Siris S. Do antipsychotic drugs influence suicidal behavior in schizophrenia? Psychopharmacol Bull. 2007; 40(3): 128-42.
55. Moller HJ. Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data. Eur Arch Psychiatr Clin Neurosci. 2005; 255(2): 83-93.
56. Keck JR, Strakowski SM, Mcelroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility and suicidality in patients with schizophrenia. J Clin Psychiatr. 2000; 61: 4-9.
57. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989; 25: 238-46.
58. Jasovic-Gasic M, Crnobaric C, Miljevic C. Antidepressants versus clozapine in the treatment of depressive syndrome in schizophrenia. Proceedings of the 10th European College of Neuropsychopharmacology Congress. 1997 Sep 13-17; Vienna, Austria.
59. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic- resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatr. 1995; 152: 183-90.
60. Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatr. 1999; 156: 1138-48.
61. Mullholand C, Lynch G, Cooper SJ. A doule-blind, placebo-controlled trial of sertraline for depressive symptoms in stable, chronic schizophrenia. Biol Psychia. 1997; 42: 188.
62. Siris SG, Addington D, Azorin J, Fallon IR, Gerlach J, Hirsch SR. Depression in schizophrenia: recognition and management in the USA. Schizophr Res. 2001; 47(2-3): 185-97.
63. Whitehead C, Moss S, Cardno A, Lewis G. Antidepressants for the treatment of depression in people with schizophrenia: a systematic review. Psychol Med. 2003; 33: 589-99.
64. Siris SG. Assessment and treatment of depression in schizophrenia: a depression-like syndrom often occurs during the longitudinal course of patients with operationally diagnosed cases of schizophrenia. Psychiatric Ann. 1994; 24: 463-7.
65. Kasckow JW, Mohamed S, Thallasinos A, Carroll B, Zisook S, Jeste DV. Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. Int J Geriatr Psychiatr. 2001; 16(12): 1163-7.
66. Zisook S, Kasckow JW, Golshan S, Fellows I, Solorzano E, Lehman D, et al. Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. J Clin Psychiatr. 2009; 70(4): 562-71.
67. Kasckow J, Lanouette N, Patterson T, Fellows I, Golshan S, Solorzano E, et al. Treatment of subsyndromal depressive symptoms in middle-age and older adults with schizophrenia: effect on functioning. Int J Geriatr Psychiatr. 2010; 25(2): 183-90.
68. Maseh D, Shahal B, Safar R, Melamed Y. Venlafaxine for the treatment of depressive episode during the course of schizophrenia. J Clin Psychopharmacol. 2004; 24(6): 653-5.
69. Ciobanu AM, Dragan A, Beldie A, Calinescu E. Treatment of post-psychotic depression (PPD) in schizophrenia. Eur Psychiatr. 2008; 23: S109. Abstract only.
70. Kingdon D, Rathod S, Hansen L, Wright JH. Combining cognitive therapy and pharmacotherapy for schizophrenia. J Cogn Psychother. 2007; 21(1): 28-36.
71. Kaneda Y, Fujii A, Okura M, Nagamine I. Depressive symptoms in medicated chronic schizophrenics. Ger J Psychiatr. 1999; 2: 1-12.
72. Johnson DAW. Depression in schizophrenia: some observations on prevalence, etiology, and treatment. Acta Psychiatr Scand. 1981; 63: 137-44.
73. Rooke O, Birchwood M. Loss, humiliation and entrapment as appraisals of schizophrenic illness: a prospective study of depressed and non-depressed patients. Br J Psychol. 1998; 37: 259-68.
74. Harrow M, Yonan CA, Sands JR, Marengo J. Depression in schizophrenia: are neuroleptics, akinesia or anhedonia involved? Schizoprenia Bull. 1994; 20(2): 327-38.
75. Hogarty GE, Munetz MR. Pharmacogenic depression among outpatient schizophrenic patients: a failure to substantiate. J Clin Psychopharmacol. 1984; 4: 17-24.
76. Hirsch SR, Jooley AG, Barnes TR, Liddle PF, Curson DA, Patel A, et al. Dysphoric and depressive symptoms in chronic schizophrenia. Schizophr Res. 1989; 2: 259-64.
77. Moller HJ. Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanism? Eur Arch Psychiatr Clin Neurosci. 2005; 255(3): 190-201.
78. Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatr. 2004; 161(10): 1837-47.
79. Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatr. 2005; 162(10): 1879-87.
80. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatr. 2009; 166(2): 152-63.
81. Emsley RA, Buckley P, Jones AM, Greenwood MR. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. J Psychopharmacol. 2003; 17(2): 210-5.
82. Kasper S. Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. Depress Anxiety. 2004; 20: 44-7.
83. Furtado VA, Srihari V, Kumar A. Atypical antipsychotics for people with both schizophrenia and depression. Schizophr Bull. 2009; 35(2): 297-8.
84. Alfredsson G, Harnryd C, Wiesel FA. Effects of sulpiride and chlorpromazine on depressive symptoms in schizophrenic patients-relationship to drug concentrations. Psychopharmacology (Berl). 1984; 84(2): 237-41.